Antifolate Drugs in Cancer Therapy
In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, othe...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Totowa, NJ
Humana
1999, 1999
|
| Edition: | 1st ed. 1999 |
| Series: | Cancer Drug Discovery and Development
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 1 Antifolate Drugs: Past and Future Perspectives
- 2 Folate Biochemistry in Relation to Antifolate Selectivity
- 3 Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors
- 4 Development of Nonpolyglutamatable DHFR Inhibitors
- 5 Fluoropyrimidines as Antifolate Drugs
- 6 Raltitrexed (Tomudextm), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor: Design and Preclinical Activity
- 7 Tomudex: Clinical Development
- 8 Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514)
- 9 GW1843: A Potent, Noncompetitive Thymidylate Synthase Inhibitor—Preclinical and Preliminary Clinical Studies
- 10 Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (Thymitaqtm, AG337)
- 11 ZD9331: Preclinical and Clinical Studies
- 12 Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887
- 13 AG2034: A GARFT Inhibitor with Selective Cytotoxicity to Cells that Lack a G1 Checkpoint
- 14 Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates: Exploitation for Folate-Based Chemotherapy and Immunotherapy
- 15 Folates as Chemotherapeutic Modulators
- 16 Antifolate Polyglutamylation in Preclinical and Clinical Antifolate Resistance
- 17 Antifolates in Combination Therapy
- 18 Pharmacodynamic Measurements and Predictors of Response to Thymidylate Synthase Inhibitors
- 19 Molecular Regulation of Expression of Thymidylate Synthase
- 20 The Role of Uracil Misincorporation in Thymineless Death
- 21 Thymineless Death
- 22 Genetic Determinants of Cell Death and Toxicity